Carolyn DaSilva

Merck & Co., Inc., Rahway, NJ, USA (United States) — United States

Medicine · Health Sciences

18h-index1.6kcitations33works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Bone health and treatments(15), Bone Metabolism and Diseases(12), Bone health and osteoporosis research(11), Estrogen and related hormone effects(11), Bioactive Compounds and Antitumor Agents(7)

Publications33 total

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease
Blood·2023· 9 citedOpen Access
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
The Lancet Diabetes & Endocrinology·2019· 164 cited
Efficacy of odanacatib in postmenopausal women with osteoporosis: subgroup analyses of data from the phase 3 long-term odanacatib fracture trial (LOFT)
Bone Abstracts·2016· 1 cited
Continuous treatment with odanacatib for up to 8 years in postmenopausal women with low bone mineral density: a phase 2 study
Osteoporosis International·2016· 37 citedOpen Access
Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With Alendronate: A Randomized Placebo-Controlled Trial
The Journal of Clinical Endocrinology & Metabolism·2013· 59 cited
OP0247 Effects of Odanacatib on BMD and Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate– a Randomized Placebo-Controlled Trial
Annals of the Rheumatic Diseases·2013· 1 cited
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate- a randomized placebo-controlled trial
Bone Abstracts·2013· 1 cited
Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5year results of a phase 2 trial
Bone·2012· 9 cited
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study
Journal of Bone and Mineral Research·2012· 160 cited
Four-year results of a phase 2 study of the cathepsin K inhibitor odanacatib in postmenopausal women with low bone mineral density: Effects on bone mineral density and bone turnover markers
Bone·2011· 4 cited
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect
Journal of Bone and Mineral Research·2010· 246 citedOpen Access
Odanacatib in the Treatment of Postmenopausal Women with Low Bone Mineral Density: 3-Year Continued Therapy and Resolution of Effect
Bone·2010· 2 cited
Odanacatib in the Treatment of Postmenopausal Women with Low Bone Mineral Density: 3-Year Continued Therapy and Resolution of Effect
Journal of Clinical Densitometry·2010· 1 cited
Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density
Journal of Bone and Mineral Research·2009· 330 cited
Two-Year Results of Odanacatib (MK-822) Treatment in Postmenopausal Women with Low Bone Mineral Density
Journal of Clinical Densitometry·2009
Odanacatib treatment in postmenopausal women with low bone mineral density: 24-month results
Bone·2009
Two year results in a randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in postmenopausal women with low bone mineral density
Bone·2009· 1 cited
A Randomized, Double-Blind, Placebo-Controlled Study of Odanacatib (MK-822) In The Treatment of Postmenopausal Women With Low BMD: 18-Month Results
Journal of Clinical Densitometry·2008· 2 cited
A randomized, double-blind, placebo-controlled study of a cathepsin-K inhibitor in the treatment of postmenopausal women with Low BMD: 18 month results
Bone·2008· 3 cited
Estrogen receptor ligands. Part 16: 2-Aryl indoles as highly subtype selective ligands for ERα
Bioorganic & Medicinal Chemistry Letters·2007· 67 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Michael R. McClung(12), Nadia Verbruggen(11), Arthur C. Santora(11), Henry G. Bone(10), Elizabeth T. Birzin(10), Wanda Chan(10), Yi Yang(10), Edward C. Hayes(10), Frank DiNinno(10), Susan P. Rohrer(10), Milton L. Hammond(10), Lee-Yuh Pai(9), James M. Schaeffer(9), John A. Eisman(7), Carolyn M. Hustad(7), Albert Leung(7), Ian R. Reid(6), Antonio Lombardi(6), Timothy A. Blizzard(6), Deborah M. Gurner(5)